<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Inhibition of hepatic <z:chebi fb="15" ids="28087">glycogen</z:chebi> phosphorylase is a promising treatment strategy for attenuating <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Crystallographic studies indicate, however, that selectivity between <z:chebi fb="15" ids="28087">glycogen</z:chebi> phosphorylase in skeletal muscle and liver is unlikely to be achieved </plain></SENT>
<SENT sid="2" pm="."><plain>Furthermore, <z:chebi fb="15" ids="28087">glycogen</z:chebi> phosphorylase activity is critical for <z:mpath ids='MPATH_458'>normal</z:mpath> skeletal muscle function, and thus <z:mp ids='MP_0002899'>fatigue</z:mp> may represent a major development hurdle for this therapeutic strategy </plain></SENT>
<SENT sid="3" pm="."><plain>We have carried out the first systematic evaluation of this important issue </plain></SENT>
<SENT sid="4" pm="."><plain>The rat gastrocnemius-plantaris-soleus (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GPS</z:e>) muscle was isolated and perfused with a red cell suspension, containing 3 micromol/l <z:chebi fb="15" ids="28087">glycogen</z:chebi> phosphorylase inhibitor (GPi) or vehicle (control) </plain></SENT>
<SENT sid="5" pm="."><plain>After 60 min, the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GPS</z:e> muscle was snap-frozen (rest, n = 11 per group) or underwent 20 s of maximal contraction (n = 8, control; n = 9, GPi) or 10 min of submaximal contraction (n = 10 per group) </plain></SENT>
<SENT sid="6" pm="."><plain>GPi pretreatment reduced the activation of the <z:chebi fb="15" ids="28087">glycogen</z:chebi> phosphorylase a form by 16% at rest, 25% after 20 s, and 44% after 10 min of contraction compared with the corresponding control </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="47" ids="16027,28971">AMP</z:chebi>-mediated <z:chebi fb="15" ids="28087">glycogen</z:chebi> phosphorylase activation was impaired only at 10 min (by 21%) </plain></SENT>
<SENT sid="8" pm="."><plain>GPi transiently reduced muscle <z:chebi fb="4" ids="24996">lactate</z:chebi> production during contraction, but other than this, muscle energy metabolism and function remained unaffected at both contraction intensities </plain></SENT>
<SENT sid="9" pm="."><plain>These data indicate that <z:chebi fb="15" ids="28087">glycogen</z:chebi> phosphorylase inhibition aimed at attenuating <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> is unlikely to negatively impact muscle metabolic and functional capacity </plain></SENT>
</text></document>